Article citationsMore>>

Sacca, F., Barnett, C., Vu, T., et al. (2023) Efgartigimod Improved Health-Related Quality of Life in Generalized Myasthenia Gravis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study (ADAPT). Journal of Neurology, 270, 2096-2105.
https://doi.org/10.1007/s00415-022-11517-w

has been cited by the following article:

• TITLE: New Progress in the Treatment of Myasthenia Gravis

  AUTHORS: Yaping Sun, Xianglin Cheng

  KEYWORDS: Myasthenia Gravis, Thymusectomy, Immunosuppressive Drug, Biological Drug

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.12, December 8, 2023

  ABSTRACT: In recent decades, the treatment of myasthenia gravis has been extensively developed, but a standardized standard still needs to be used. Its treatment strategy is associated with patient prognosis, economic costs, and complications. This article reviews the pathogenesis, treatment methods, and complications of myasthenia gravis, providing new ideas for diagnosing and treating myasthenia gravis and fully embodies the principle of safety and precision.